In patients treated with TMZ, whether used in combination with RT or as monotherapy following RT for newly-diagnosed glioblastoma multiforme, or as monotherapy in patients with recurrent or progressive glioma, the reported very common adverse reactions were similar: nausea, vomiting, constipation, anorexia, headache and fatigue.
Hos patienter med nyligt diagnosticeret glioblastom multiforme, der fik TMZ samtidig med strålebehandling eller som monoterapi, blev udslæt rapporteret som værende meget almindeligt.